Highlights Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Market Closed - Nasdaq Other stock markets 02:00:01 19/06/2024 am IST			5-day change	1st Jan Change
1.94 ^USD	-6.73%		-6.28%	-53.81%

20/05	Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index	CI
17/05	First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

First Wave BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data	14/03	MT
First Wave BioPharma, Inc. completed the acquisition of ImmunogenX, LLC for $57.9 million.	13/03	CI
First Wave BioPharma Investors Exercise Warrants at Reduced Price -- Shares Up	28/12	MT
First Wave BioPharma Shares Skyrocket After Selling Prospective Treatment for Inflammatory Bowel Diseases	27/12	MT
First Wave BioPharma, Inc. signed a non-binding term sheet to acquire ImmunogenX, LLC.	18/12	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
First Wave BioPharma Signs License Agreement With Sanofi for Capeserod	14/23/14	MT
First Wave Biopharma, Inc. Announces Exclusive Global License Agreement for Capeserod from Sanofi	14/23/14	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation	13/23/13	CI
First Wave BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis	11/23/11	CI
First Wave BioPharma, Inc. Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis	25/23/25	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
First Wave Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
First Wave BioPharma, Inc. Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation	09/23/09	CI
First Wave BioPharma, Inc. Announces Phase 2 Adrulipase Combination Trial Data	21/23/21	CI
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis	02/23/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Highlights

Filters